Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
NCT06982352
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis (AD)
- Psoriasis (PsO)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- LAPIX Therapeutics Inc.
- Last updated on ClinicalTrials.gov
- December 19, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Dakota · 1
- Red River Research Partners · Fargo, ND
Texas · 1
- Clinical Investigations of Texas · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.